Second lady's 2025 reading challenge targets declining reading scores among students
America's second lady Usha Vance has announced the "Summer Reading Challenge," encouraging children across the country to open up a book this summer.
"Adventure, imagination, and discovery await – right between the pages of a book," writes the second lady in a letter.
"We are excited to invite all children (K-8) to participate in the Second Lady's 2025 Summer Reading Challenge," the letter continues.
Second Lady Usha Vance On Mother's Day And What She Strives For As A Mom
Children are encouraged to read 12 books of their choice between June 1 and Sept. 5 — and track their progress through a reading log issued by the White House.
Nicole Reeves, communications director for the second lady, told Fox News Digital that Ms. Vance is very excited to announce this project in the hope of engaging young readers throughout the summer.
Read On The Fox News App
"It is essential that we encourage our youth to continue learning outside of the classroom, and this challenge provides an excellent opportunity to do so," Reeves added.
In the log of their progress, students must list the book titles and author, the date they finished reading the books, and a brief reflection about the favorite book they read.
For more Lifestyle articles, visit foxnews.com/lifestyle
The National Center for Education Statistics found in a 2022 report that the average reading scores among 9-year-old students declined five points compared to 2020, marking the largest average score decline in reading since 1990.
Approximately 40% of U.S. students cannot read at a basic level, according to the National Literacy Institute.
It was also found that almost 70% of low-income fourth grade students cannot read at a basic level.
Click Here To Sign Up For Our Lifestyle Newsletter
The institute also found that "struggling readers" suffer both socially and emotionally.
Reading promotes positive mental health outcomes, helping reduce stress and anxiety, according to the Baylor College of Medicine (BCM).
Children who complete the Second Lady's 2025 Summer Reading Challenge will receive a personalized certificate and a small prize.
They will also be entered in a drawing for a chance to visit Washington, D.C., with a chaperone.Original article source: Second lady's 2025 reading challenge targets declining reading scores among students
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
4 hours ago
- New York Post
This common kitchen herb ingredient could help target or slow Alzheimer's
Experts believe they've identified a chemical compound in certain herbs that could help mitigate or prevent Alzheimer's disease — but before anyone makes a run for the spice rack, there are a few catches. In a study published in the journal Antioxidants earlier this year, researchers from the Scripps Research Institute identified a compound called carnosic acid, which is prevalent in rosemary and sage. Advertisement The compound could prove therapeutic for neurodegenerative disorders, including Alzheimer's disease, the experts concluded. Carnosic acid contains 'striking antioxidant [and] anti-inflammatory properties,' the researchers wrote in the findings. Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, based in California, spoke with Fox News Digital about the results. 'In this study, we observed that administering this drug to mice that had advanced Alzheimer's-like disease significantly improved the number of neurons, as well as the number of synapses or connections between the brain cells,' the team said. Advertisement 4 Experts believe they've identified a chemical compound, carnosic acid, in certain herbs like rosemary and sage that could help mitigate or prevent Alzheimer's disease. Brent Hofacker – The experts added, 'It also reduced inflammation that is caused by the current anti-amyloid antibody therapies. We also observed an improvement in the learning and memory behavior of the mice that received the drug.' Banerjee and Lipton also noted that carnosic acid is a 'prodrug,' meaning it's inactive at first — but once it enters the body, it's activated by oxidative and inflammatory stress. 'It specifically targets cells undergoing oxidative and inflammatory stress, without affecting the healthy, normal brain cells,' Banerjee said. Advertisement 'This further makes it a safe option for therapeutics.' The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains. There are cautions, however. Advertisement Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, told Fox News Digital that studies based on a mouse model of Alzheimer's can be helpful but are not conclusive. 4 Experts say carnosic acid could improve inflammation occurring in most aging brains. LIGHTFIELD STUDIOS – 'Models are important in helping us understand the basic biology of the disease, but we need human studies in representative populations for ideas to be fully validated,' Kloske said. 'Therefore, while these are intriguing findings, more research is needed to understand the impacts and outcomes of these compounds on people living with, or at risk for, Alzheimer's.' Cooking sage and rosemary won't provide the full anti-inflammatory effects, Banerjee and Lipton stressed. 4 'We need human studies in representative populations for ideas to be fully validated,' Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, says about the limitations of the information. – 'Critically, one cannot take sufficient herbs safely to produce the same effect as our new drug,' Banerjee said. The study, funded in part by the National Institutes of Health, did have some limitations, the researchers acknowledged. Advertisement Kloske advised that, at this point, 'no one should consume these herbs (or carnosic acid) to prevent or treat Alzheimer's or other cognitive impairment.' 4 According to Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, cooking sage and rosemary won't provide the full anti-inflammatory effects. Ganna – Dr. Lee Murray, a neurologist in Jackson, Tennessee, echoed Kloske's concerns. 'Before patients start incorporating rosemary and sage in every dish they eat, we need to remember these studies are pre-clinical,' Murray told Fox News Digital. Advertisement 'Currently, there is insufficient clinical evidence to recommend rosemary and sage as a standard therapy for Alzheimer's dementia.' Murray, however, said the data 'is encouraging' and opens the door to additional pathways for potential therapeutics. Banerjee said she hopes that 'our drug will start human clinical trials soon.' She added, 'If it proves to be effective, it will be a great new drug for those suffering from Alzheimer's … From the results of our animal studies, we are cautiously optimistic for its success in human clinical trials.'
Yahoo
a day ago
- Yahoo
3 Reasons Warren Buffett Might Buy UnitedHealth Group Stock
UnitedHealth Group's stock has plummeted to multiyear lows. Rising costs and a change in leadership have weighed down the shares. Its fundamentals, however, still look solid. 10 stocks we like better than UnitedHealth Group › The stock of UnitedHealth Group (NYSE: UNH) is trading around its five-year lows. It plummeted after posting poor earnings numbers earlier this year amid rising costs. It has also withdrawn its guidance, changed its CEO, and the Department of Justice is reportedly looking into its billing practices. There has been a flurry of negative news around the business in recent months, which has made investors bearish on this once seemingly safe health insurance company. Warren Buffett, CEO of Berkshire Hathaway, likes to invest in stocks when they are struggling. As long as their financials are in good shape and the future of the business is still encouraging, an underperforming stock can be a good addition to Berkshire's portfolio. Here are three reasons I believe Buffett may want to buy the stock right now. Buffett likes to stay within his circle of competence when investing so he's focusing on businesses he understands well. And one thing he understands well is insurance. Berkshire Hathaway owns GEICO, one of the best known insurance companies in the country. There can be a bit more complexity when it comes to health insurance, but it could still be an enticing option for Buffett to consider, especially given that UnitedHealth is one of the largest health insurers in the country. Its role in the healthcare industry is huge, and its strong position gives it a competitive moat. The overall long-term safety and stability that comes with insurance companies could make UnitedHealth an attractive addition to the Berkshire portfolio. Buffett likes to invest in businesses that have strong numbers, and that's a nonnegotiable consideration. Not only do the financials need to look good, but there also needs to be a lot of predictability in a company's growth. The insurer has been facing adversity in recent years due to rising costs, but it has continually generated strong margins. Over the trailing 12 months, the healthcare company reported profits totaling $22 billion on revenue of $410 billion, for a profit margin of more than 5%. Single-digit margins have been typical for UnitedHealth, but as the company grows its business and insures more people, its bottom line is likely to increase. Even with the challenges ahead, the company believes it can continue to have long-term growth ranging from 13% to 16% per year. The dividend yield is 2.9% today, which is higher than average because of the stock's decline this year -- it had fallen 40% as of June 20. Its yield is now more than double the 1.3% that you can get with the average S&P 500 stock. And it is also a dividend growth stock. Its current quarterly payout is $2.21 a share, which is 77% higher than the $1.25 it was paying five years ago. That averages out to a compound annual growth rate of more than 12%. While Berkshire may not like to pay dividends, it invests in many companies that do. UnitedHealth is a stock I could see Buffett buying today, due to its beaten-down valuation and attractive fundamentals. Although the short term may look concerning, this is an investment that can make a lot of sense over the long term. And even if Buffett doesn't end up buying the stock, you may still want to consider adding it to your portfolio. At just 13 times its trailing earnings, you can get it at a fairly attractive price. While it may still be a challenging road ahead, UnitedHealth Group's strong financials and position atop the healthcare industry should enable it to do well and continue to grow over the long haul. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor's total average return is 809% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. 3 Reasons Warren Buffett Might Buy UnitedHealth Group Stock was originally published by The Motley Fool Sign in to access your portfolio
Business Wire
2 days ago
- Business Wire
Healthpeak Properties Announces Second Quarter 2025 Earnings Release Date and Conference Call Details
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report second quarter 2025 financial results after the close of trading on the New York Stock Exchange on Thursday, July 24, 2025. Healthpeak will host a conference call and webcast on Friday, July 25, 2025, at 8:00 a.m. Mountain Time (10:00 a.m. Eastern Time) to review its financial performance and operating results. The conference call can be accessed in the following ways: Healthpeak's website: Webcast: Joining via webcast is recommended for those who will not be asking questions. Telephone: The participant dial-in number is (800) 715-9871. An archive of the webcast will be available on Healthpeak's website through July 24, 2026, and a telephonic replay can be accessed through August 1, 2025, by dialing (800) 770-2030 and entering conference ID number 95156. ABOUT HEALTHPEAK PROPERTIES Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery. For more information regarding Healthpeak, visit
